This study was to map the current literature on the use of SGLT2 inhibitors such as empagliflozin and dapagliflozin for the prevention of CSA-AKI, identify evidence gaps, and inform future research directions. This evidence concerns the gene SLC5A2 and chromosome-type aberration frequency.